エピソード

  • EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances

    EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances
    2026/04/27

    Featuring perspectives from Dr Suresh S Ramalingam and Dr Helena Yu, including the following topics:

    • Introduction: Genomics of EGFR (and HER2) (0:00)
    • Metastatic Disease (9:30)
    • Localized Disease (30:22)
    • EGFR Exon 20 Insertion Mutations (46:57)
    • New Agents (54:20)

    CME information and select publications
    続きを読む 一部表示
    57 分
  • EGFR-Mutant Non-Small Cell Lung Cancer | Suresh S Ramalingam, MD

    EGFR-Mutant Non-Small Cell Lung Cancer | Suresh S Ramalingam, MD
    2026/04/27

    Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in EGFR-Mutant Non-Small Cell Lung Cancer | Faculty Presentation 2: Other Relevant Topics in EGFR-Mutant NSCLC (eg, Nonmetastatic Disease, Exon 20 Insertion Mutations, Novel Agents) — Suresh S Ramalingam, MD

    CME information and select publications
    続きを読む 一部表示
    26 分
  • EGFR-Mutant Non-Small Cell Lung Cancer | Helena Yu, MD

    EGFR-Mutant Non-Small Cell Lung Cancer | Helena Yu, MD
    2026/04/27

    Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in EGFR-Mutant Non-Small Cell Lung Cancer | Faculty Presentation 1: Management of Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) — Helena Yu, MD

    CME information and select publications
    続きを読む 一部表示
    30 分
  • Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium

    Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
    2026/04/25

    Featuring perspectives from Dr Jaffer A Ajani, Dr Samuel J Klempner, Dr Rutika Mehta and Dr John Strickler, moderated by Dr Klempner, including the following topics:

    • Role of PD-L1 status, tumor histology and pulmonary disease in selection of immune checkpoint inhibition as up-front therapy (0:00)
    • Impact of metastatic site and autoimmune disease on clinical decision-making in the use of immune checkpoint inhibition (5:56)
    • Biomarker assessment approach and treatment selection (10:50)

    CME information and select publications
    続きを読む 一部表示
    17 分
  • Prostate Cancer — Year in Review Series on Relevant New Datasets and Advances

    Prostate Cancer — Year in Review Series on Relevant New Datasets and Advances
    2026/04/23

    Featuring perspectives from Dr Andrew J Armstrong and Dr Scott T Tagawa, including the following topics:

    • Introduction: Evolution of the Prostate Cancer Model; Prostate Cancer Working Group 4 (PCWG4) (0:00)
    • Hormonal Therapy (5:48)
    • Chemotherapy (Docetaxel) (26:38)
    • PARP Inhibition (29:49)
    • Radioligand Therapy (36:56)
    • New Agents (43:37)

    CME information and select publications
    続きを読む 一部表示
    58 分
  • Prostate Cancer | Scott T Tagawa, MD, MS

    Prostate Cancer | Scott T Tagawa, MD, MS
    2026/04/23

    Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Prostate Cancer | Faculty Presentation 2: Other Available and Emerging Therapeutic Approaches — Scott T Tagawa, MD, MS

    CME information and select publications
    続きを読む 一部表示
    25 分
  • Prostate Cancer | Andrew J Armstrong, MD, ScM

    Prostate Cancer | Andrew J Armstrong, MD, ScM
    2026/04/23

    Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Prostate Cancer | Faculty Presentation 1: Optimizing the Role of Hormonal Therapy in the Care of Patients with Prostate Cancer — Andrew J Armstrong, MD, ScM

    CME information and select publications
    続きを読む 一部表示
    24 分
  • Menin Inhibitors in Acute Myeloid Leukemia — Year in Review Series on Relevant New Datasets and Advances

    Menin Inhibitors in Acute Myeloid Leukemia — Year in Review Series on Relevant New Datasets and Advances
    2026/04/20

    Featuring perspectives from Dr Amir Fathi and Dr Eunice S Wang, including the following topics:

    • Introduction: Overview — Biopharmacologic Considerations (0:00)
    • Menin Inhibitor Monotherapy (21:51)
    • Differentiation Syndrome (36:12)
    • Menin Inhibitor Combination Approaches (45:15)
    • Future Directions (49:59)
    • PARADIGM — Randomized Phase II Trial (53:24)

    CME information and select publications
    続きを読む 一部表示
    59 分